Cancer-related fatigue after treatment of pediatric brain tumor
Conditions
Brief summary
Changes in patient self-reported or parent proxy-reported fatigue from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).
Detailed description
Changes from baseline in self and parent-reported executive function measured by the BRIEF-2., Changes from baseline in digital measures of sustained attention and executive function., Changes from baseline in standardized neurocognitive measures of processing speed and working memory., Changes from baseline in self and parent-reported measures of Health Related Quality of Life measured by the PedsQL 4.0 Generic Core Scales Module., Time spent within different activity domains and sleep-wake patterns measured by actigraphy., Changes from baseline in self and parent-reported side-effects measured by Barkley’s Side-Effects Rating Scale.
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in patient self-reported or parent proxy-reported fatigue from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline in self and parent-reported executive function measured by the BRIEF-2., Changes from baseline in digital measures of sustained attention and executive function., Changes from baseline in standardized neurocognitive measures of processing speed and working memory., Changes from baseline in self and parent-reported measures of Health Related Quality of Life measured by the PedsQL 4.0 Generic Core Scales Module., Time spent within different activity domains and sleep-wake patterns measured by actigraphy., Changes from baseline in self and parent-reported side-effects measured by Barkley’s Side-Effects Rating Scale. | — |
Countries
Denmark